Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)

NCT00160069 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00160069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
April 30, 2009
Enrollment
128 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung